Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP-C1
- Development stage
- Phase 2
- Lead developer
- Meabco
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
BP-C1 is a novel platinum-containing anticancer agent developed for intramuscular administration. Its active substance is a cis-diammineplatinum(II) complexed with a polymer containing benzene polycarboxylic acids derived from lignin. This amphiphilic polymer confers improved pharmacological properties compared to traditional platinum analogues such as cisplatin and carboplatin, including reduced systemic toxicity and side effects while maintaining or improving antitumor efficacy. Mechanistically, BP-C1 acts as a DNA inhibitor by forming DNA adducts that disrupt cancer cell replication and survival. It has demonstrated broad-spectrum antitumor activity in preclinical models and is being developed primarily for the palliative treatment of metastatic breast cancer and metastatic pancreatic cancer[5][6][4].
- Brand names
- BP-C1BP-C-1BP-C 1
- Other names
- BP-Cx1-platinum complexBP-Cx-1-platinum complexBP-Cx 1-platinum complexcis-diammineplatinum(II) complex with benzene polycarboxylic acids polymer
02
Targets
DNA
Beyond the preview
Go deeper on BP-C1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP-C1.